GeneDx Holdings (WGS) Total Debt (2020 - 2026)

GeneDx Holdings (WGS) has reported Total Debt for 7 consecutive years, with $100.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Debt rose 80.34% year-over-year to $100.0 million; the TTM figure through Mar 2026 stood at $100.0 million (up 80.34% YoY), while the FY2025 annual figure was $48.2 million, down 7.2% from the prior year.
• Total Debt climbed to $100.0 million in Q1 2026 per WGS's latest filing, from $48.2 million in the prior quarter.
• Across five years, Total Debt topped out at $100.0 million in Q1 2026 and bottomed at $6.1 million in Q3 2023.
• Historically, Total Debt has averaged $38.1 million across 5 years, with a median of $51.9 million in 2024.
• Annual changes were most pronounced in 2023 — Total Debt slumped 53.2% — and 2024, when it soared 759.78%.
• GeneDx Holdings' Total Debt stood at $9.8 million in 2022, then soared by 435.28% to $52.7 million in 2023, then decreased by 1.47% to $51.9 million in 2024, then decreased by 7.2% to $48.2 million in 2025, then surged by 107.57% to $100.0 million in 2026.
• Business Quant data shows WGS's Total Debt at $100.0 million in Q1 2026, $48.2 million in Q4 2025, and $54.8 million in Q3 2025.